Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
Malaria
About this trial
This is an interventional prevention trial for Malaria focused on measuring Healthy Subjects, Vaccine-Mediated Protection, Immunogenicity, Sporozoites, Parasitemia
Eligibility Criteria
- INCLUSION CRITERIA:
A volunteer must meet all of the following criteria to be included:
- 18 to 45 years old adults.
- Able and willing to participate for the duration of the study.
- Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
- Able and willing to complete the informed consent process.
- Willing to donate blood for sample storage to be used for future research.
- Willing to refrain from blood donation to blood banks for 3 years following P. falciparum CHMI.
- Agrees not to travel to a malaria endemic region during the entire course of study participation.
- Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) less than or equal to 35 for vaccine groups or BMI less than or equal to 40 for control groups.
If enrolling into a Group with an IV vaccination schedule, then the physical exam must include assessment that there is adequate bilateral antecubital fossa venous access.
Laboratory Criteria within 56 days prior to enrollment:
- Hemoglobin greater than or equal to 11.2 g/dL for women; greater than or equal to 12.6 g/dL for men.
- Differential and platelet count either within institutional normal range or accompanied by site physician approval.
- Alanine aminotransferase (ALT) less than or equal to 1.25 x upper limit of normal (ULN) for vaccine groups or less than or equal to 1.75 x ULN for CHMI control groups.
- Serum creatinine less than or equal to upper limit of normal.
Negative for HIV infection.
Laboratory Criterion documented any time prior to enrollment:
Negative sickle cell screening test.
Female-Specific Criteria:
- Negative Beta-HCG pregnancy test (urine or serum) on day of enrollment for women presumed to be of childbearing potential.
- A woman of childbearing potential must agree to use an effective means of birth control throughout the duration of study participation.
EXCLUSION CRITERIA:
A volunteer will be excluded if one or more of the following conditions apply:
- Woman who is breast-feeding or planning to become pregnant during the time interval needed to complete the study.
- Receipt of a malaria vaccine in a prior clinical trial.
- Any history of malaria infection.
- Evidence of increased cardiovascular disease risk; defined as >10% five year risk by the non-laboratory method.
- Current use of systemic immunosuppressant pharmacotherapy.
- History of a splenectomy, sickle cell disease or sickle cell trait.
- Plan for major surgery between enrollment and challenge.
- Known allergy to any component of the vaccine formulation; history of anaphylactic response to mosquito-bites; or known allergy to chloroquine phosphate, atovaquone or proguanil.
- Participation in any study involving another investigational vaccine or drug within 12 weeks prior to enrollment, or plan to participate in another investigational vaccine/drug research during the study.
- Personal beliefs that prohibit the receiving of vaccine product containing human serum albumin within the diluent.
- Use or planned use of any drug with anti-malarial activity that would coincide with study vaccination or challenge.
- History of psoriasis or porphyria, which may be exacerbated after treatment with chloroquine.
- Anticipated use of medications known to cause drug reactions with chloroquine or atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and kaolin.
- Psychiatric condition that precludes compliance with the protocol; past or present psychoses; disorder requiring lithium; or within five years prior to enrollment, history of a suicide plan or attempt.
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent or to comply with the protocol schedule.
Sites / Locations
- University of Maryland Center for Vaccine Dev, Baltimore
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
No Intervention
1, 4, 5, 6, 7
2
3
8
Vaccination schedules with 3 to 4 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
Vaccination schedules 4 IM vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
Participation in controlled human malari infection (CHMI) without prior vaccinations to serve as controls.